Eligibility Type 2 Diabetes Mellitus NCT00254254

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
treatment with diet and exercise alone or a stable dose of metformin, or sulfonylurea, or metformin plus a sulfonylurea for at least 3 months.
Beschrijving

Diabetes Treatment

Datatype

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0011849
has hba1c 6.0% to 11.0%, inclusive, at screening.
Beschrijving

HbA1c

Datatype

boolean

Alias
UMLS CUI [1]
C0019018
has a body weight of >= 50 kg at screening.
Beschrijving

BMI

Datatype

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
received any investigational drug or has participated in any type of clinical trial within 3 months prior to screening.
Beschrijving

Experimental Drug and Study Participation Status

Datatype

boolean

Alias
UMLS CUI [1]
C0304229
UMLS CUI [2]
C2348568
currently participates in any other interventional study.
Beschrijving

Study Participation Status

Datatype

boolean

Alias
UMLS CUI [1]
C2348568
is currently treated with any of the following excluded medications:
Beschrijving

Pharmacotherapy

Datatype

boolean

Alias
UMLS CUI [1]
C0013216
sulfonylurea chlorpropamide
Beschrijving

Sulfonylurea, chlorpropamide

Datatype

boolean

Alias
UMLS CUI [1]
C0038766
UMLS CUI [2]
C0008287
thiazolidinedione within 3 months of screening.
Beschrijving

Thiazolidinedione

Datatype

boolean

Alias
UMLS CUI [1]
C1257987
αlpha glucosidase inhibitor within 3 months of screening.
Beschrijving

Alpha glucosidase inhibitor

Datatype

boolean

Alias
UMLS CUI [1]
C3539108
meglitinide within 3 months of screening.
Beschrijving

Meglitinide

Datatype

boolean

Alias
UMLS CUI [1]
C0065880
insulin within 3 months of screening.
Beschrijving

Insulin

Datatype

boolean

Alias
UMLS CUI [1]
C0021641
pramlintide within 3 months of screening.
Beschrijving

Pramlintide

Datatype

boolean

Alias
UMLS CUI [1]
C0537551

Similar models

Eligibility Type 2 Diabetes Mellitus NCT00254254

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Treatment
Item
treatment with diet and exercise alone or a stable dose of metformin, or sulfonylurea, or metformin plus a sulfonylurea for at least 3 months.
boolean
C0087111 (UMLS CUI [1,1])
C0011849 (UMLS CUI [1,2])
HbA1c
Item
has hba1c 6.0% to 11.0%, inclusive, at screening.
boolean
C0019018 (UMLS CUI [1])
BMI
Item
has a body weight of >= 50 kg at screening.
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Experimental Drug and Study Participation Status
Item
received any investigational drug or has participated in any type of clinical trial within 3 months prior to screening.
boolean
C0304229 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
Study Participation Status
Item
currently participates in any other interventional study.
boolean
C2348568 (UMLS CUI [1])
Pharmacotherapy
Item
is currently treated with any of the following excluded medications:
boolean
C0013216 (UMLS CUI [1])
Sulfonylurea, chlorpropamide
Item
sulfonylurea chlorpropamide
boolean
C0038766 (UMLS CUI [1])
C0008287 (UMLS CUI [2])
Thiazolidinedione
Item
thiazolidinedione within 3 months of screening.
boolean
C1257987 (UMLS CUI [1])
Alpha glucosidase inhibitor
Item
αlpha glucosidase inhibitor within 3 months of screening.
boolean
C3539108 (UMLS CUI [1])
Meglitinide
Item
meglitinide within 3 months of screening.
boolean
C0065880 (UMLS CUI [1])
Insulin
Item
insulin within 3 months of screening.
boolean
C0021641 (UMLS CUI [1])
Pramlintide
Item
pramlintide within 3 months of screening.
boolean
C0537551 (UMLS CUI [1])